NCT03646188 2026-04-16
Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)
SkinJect, Inc.
Phase 1 Terminated
Clinical Trials
95 trialsNCT03737734 2026-04-06
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)
Alpha Tau Medical LTD.
Phase NA Active not recruiting
NCT04480645 2026-03-24
CivaDerm(TM) Surface Therapy Pilot Study
CivaTech Oncology
Phase EARLY_PHASE1 Completed
NCT04066504 2026-03-18
NISSO
Sun Pharmaceutical Industries Limited
Completed
NCT07227350 2026-03-10
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Philogen S.p.A.
Phase 2 Not yet recruiting
NCT06919809 2026-03-09
Effectiveness and Safety of X A-DERMâ„¢ Microsurfaced Acellular Dermal Matrix for Wound Healing After MOHS Surgery
McGuire Institute
Phase NA Completed
NCT07227870 2026-03-09
L19IL2/TNF in Patients With Basal Cell Carcinoma
Philogen S.p.A.
Phase 2 Not yet recruiting
NCT04349436 2026-02-27
ARTACUS
Replimune Inc.
Phase 1/2 Recruiting
NCT07428941 2026-02-24
LegitHealth PH
AI Labs Group S.L
Completed
NCT06422936 2026-01-26
SPOTLIGHT204
Highlight Therapeutics
Phase 2 Active not recruiting
NCT03889912 2026-01-21
Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
Regeneron Pharmaceuticals
Phase 1 Completed
NCT03886181 2025-12-08
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)
Alpha Tau Medical LTD.
Phase NA Terminated
NCT04916002 2025-12-05
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Regeneron Pharmaceuticals
Phase 2 Terminated
NCT03889899 2025-12-02
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
Alpha Tau Medical LTD.
Phase NA Recruiting
NCT04540588 2025-12-02
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
Alpha Tau Medical LTD.
Phase NA Completed
NCT06132191 2025-11-20
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Regeneron Pharmaceuticals
Approved for marketing
NCT04272034 2025-10-16
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT03836105 2025-10-15
CASE
Regeneron Pharmaceuticals
Completed
NCT06880848 2025-09-24
Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China
Jemincare
Phase 4 Completed
NCT05086692 2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05592626 2025-07-09
START-001
Marengo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05188729 2025-06-18
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT03897036 2025-05-20
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
Senhwa Biosciences, Inc.
Phase 1 Completed
NCT00472459 2025-04-18
Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Galderma R&D
Phase 3 Completed
NCT03132636 2025-04-08
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Regeneron Pharmaceuticals
Phase 2 Completed
NCT05741073 2025-03-12
Outcome Research of a European Registry Platform on Real-world Treatment Data of Patients with Advanced NMSC
EuMelaReg gGmbH
Recruiting
NCT04534127 2025-02-07
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
Alpha Tau Medical LTD.
Phase NA Recruiting
NCT04969419 2025-01-14
Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
Momentum Data
Completed
NCT04470726 2024-12-27
NMSC
AiViva BioPharma, Inc.
Phase 1/2 Completed
NCT06690086 2024-12-09
DERM-SUCCESS
DermaSensor, Inc.
Completed
NCT04068155 2024-11-22
Alpha Radiation Emitters Device for the Treatment of of Malignant Cutaneous Tumors
Alpha Tau Medical LTD.
Phase NA Recruiting
NCT04308395 2024-09-24
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
Sol-Gel Technologies, Ltd.
Phase 3 Terminated
NCT06344052 2024-09-20
To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
Stamford Pharmaceuticals, Inc.
Phase 2 Recruiting
NCT04893486 2024-08-29
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
Palvella Therapeutics, Inc.
Phase 2 Completed
NCT00472043 2024-08-06
PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma
Galderma R&D
Phase 3 Completed
NCT00472108 2024-08-05
Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma
Galderma R&D
Phase 3 Completed
NCT04925713 2024-08-02
IFx-Hu2.0 for the Treatment of Patients With Skin Cancer
TuHURA Biosciences, Inc.
Phase 1 Completed
NCT03703310 2024-07-03
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
Sol-Gel Technologies, Ltd.
Phase 3 Completed
NCT03509415 2024-04-16
Reflectance Confocal Microscopy to Diagnose BCC
Skin Care Network Ltd.
Completed
NCT04416516 2024-04-10
Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor
Ascend Biopharmaceuticals Ltd
Phase 2 Completed
NCT04669808 2024-03-18
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
Sirnaomics
Phase 2 Completed
NCT06271603 2024-02-22
ECOBASO
Damae Medical
Phase NA Unknown
NCT04362722 2023-10-10
DUNCAN
Philogen S.p.A.
Phase 2 Unknown
NCT05329792 2023-10-06
IntriNSiC
Philogen S.p.A.
Phase 2 Unknown
NCT05126173 2023-06-28
DERM US and EU Validation Study
Skin Analytics Limited
Completed
NCT04155190 2023-05-31
An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
Sol-Gel Technologies, Ltd.
Phase 2 Terminated
NCT04928222 2023-04-14
Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)
SkinJect, Inc.
Phase 1/2 Active not recruiting
NCT03208296 2023-02-06
Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)
Ascend Biopharmaceuticals Ltd
Phase 1/2 Suspended
NCT04918381 2023-01-11
CellFX Treat & Resect Low-Risk BCC Feasibility Study
Pulse Biosciences, Inc.
Phase NA Completed
NCT00473343 2023-01-05
Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
Galderma R&D
Phase 3 Completed